X
skip to main content
Life Sciences

Lessons from the supply chain

06/2022
supply chain

The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds. But, behind the headlines, how is the pandemic affecting attitudes to risk?

From governments to corporates, the importance of a diversified supply chain has been a big lesson of the pandemic. At the start, the global supply chain was tested as governments around the world urgently tried to buy personal protective equipment (PPE), test kits and other medical devices. With various countries limiting exports of products from drugs to PPE, the tension between national priorities and globalised free markets has become abundantly clear.

For governments, ways to manage health security more closely and bring production of life science products closer to home will be a big question as the dust settles on this pandemic. For life science companies, a focus on local supply and diversification are two key themes in corporate risk mitigation efforts, after experiencing first-hand the risks posed to their supply chains by government interventions, lockdowns and competition for resources.

With attention shifting to vaccines, the downstream supply chain is now where some of the most significant risks reside. With some vaccines needing to be stored at very cold temperatures, the pressure is on within the supply chain. If temperatures, among other parameters such as vibration and humidity, are not properly maintained when drugs are transported, it can lead to batches being thrown away.

Read the “Lessons from the Supply Chain” report to get an insight into how sourcing challenges during the pandemic is changing attitudes to risk in the supply chain, and ultimately changing the shape of the supply chain itself.

 

Key takeaways

  • Tensions over vaccine supply timelines emphasize the importance of drafting clear contracts.
  • Claims arise when pharma products fall outside of set parameters, such as temperature limits, during transit.
  • If a shipment’s value includes research and development (R&D) costs, liability can become contentious.
  • From governments to corporates, diversification of suppliers and near-shoring are being discussed.

 

Report
Report

Lessons from the supply chain

This content is brought to you by Chubb Insurance Malaysia Berhad, Registration No. 197001000564 (9827-A) (“Chubb”) as a convenience to readers and is not intended to constitute advice or recommendations upon which a reader may rely. Any references to insurance cover are general in nature only and may not suit your particular circumstances. Chubb does not take into account your personal objectives, financial situation or needs and any insurance cover referred to is subject to the terms, conditions and exclusions set out in the relevant policy wording. Please obtain and read carefully the relevant insurance policy before deciding to acquire any insurance product. A policy wording can be obtained at www.chubb.com/my, through your broker or by contacting any of the Chubb offices or Chubb agents. Chubb makes no warranty or guarantee about the accuracy, completeness, or adequacy of this content. It is the responsibility of the reader to evaluate the quality and accuracy of material herein.

© 2023 Chubb. Not all coverages available in all jurisdictions. Chubb® and its respective logos, and Chubb. Insured.SM are protected trademarks of Chubb.

Contact us
Contact us

Have a question or need more information?

Contact us to find out how we can help you get covered against potential risks